



(D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] improves hippocampal gene expression and cognition in a mouse model of type 1 diabetes

Nupur Pathak¹, Nigel Irwin², Varun Pathak¹, Victor Alan Gault¹, Peter Raymond Flatt¹

ABSTRACT

Objective: Oxyntomodulin (Oxm) is a gastrointestinal hormone with recently noted therapeutic potential for type 1 diabetes mellitus (T1DM). The present study examined the effects of a stable Oxm analogue on anxiety, exploratory behavior, cognitive function, hippocampal gene expression and metabolic control in a mouse model of T1DM. **Methods:** Effects of twice daily administration of the stable Oxm analogue, (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL], was assessed in insulin-deficient streptozotocin (STZ)-induced T1DM mice. **Results:** Induction of diabetes by STZ injection significantly ($P < 0.05$) impaired learning and memory compared to normal control mice. However, (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] treatment completely reversed this detrimental effect. Anxiety levels and exploratory behavior were not significantly different between all groups of mice. Hippocampal gene expression of MASH1, SYP and mTOR were reduced ($P < 0.01$ to $P < 0.001$) in T1DM mice, but significantly ($P < 0.05$ to $P < 0.001$) enhanced by twice daily (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] intervention. Moreover, expression of SYP, mTOR and IRS-1 were significantly elevated ($P < 0.05$ to $P < 0.001$) in (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] mice compared to both STZ and lean controls. These effects were accompanied by improved ($P < 0.001$) glucose tolerance and insulin sensitivity compared to STZ controls. **Conclusion:** The data highlight the potential of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] for the treatment of T1DM, and reveal the ability of this Oxm analogue to restore the deficits of learning and memory observed in STZ-induced T1DM.

KEY WORDS: Oxyntomodulin (Oxm); Type 1 diabetes mellitus (T1DM); Cognition; Hippocampus

¹School of Biomedical Sciences
University of Ulster Coleraine,
Northern Ireland, UK.

²School of Pharmacy and
Pharmaceutical Sciences University of
Ulster Coleraine, Northern Ireland, UK.

Address for correspondence:
Nigel Irwin,
School of Pharmacy and
Pharmaceutical Sciences University of
Ulster Coleraine, BT521SA, Northern
Ireland, UK.
n.irwin@ulster.ac.uk

Received: January 13, 2016

Accepted: February 05, 2016

Published: --

INTRODUCTION

Oxyntomodulin (Oxm) is a proglucagon derived gut peptide secreted by enteroendocrine L-cells in response to feeding, which is known to activate both glucagon and GLP-1 receptors [1]. Accumulating evidence suggests that stable Oxm analogues represent an attractive potential therapeutic option for obesity and related metabolic disease [2]. As such, numerous studies confirm that through glucagon receptor activation, Oxm induces catabolic effects that favor weight loss, while glucose homeostasis is improved through activation of GLP-1 receptors [1]. To capitalize on this therapeutic profile, we have recently developed (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL], an enzymatically stable Oxm analogue, with a significantly a protracted *in vivo* biological action profile [3].

Despite a clear for use of stable Oxm analogues for the treatment of type 2 diabetes, effectiveness in insulin-deficient type 1 diabetes mellitus (T1DM) is unknown. Thus, it might seem implausible that up-regulation of glucagon receptor signaling would be advantageous in T1DM. However, activation of GLP-1 receptors on both alpha- and beta-cells by Oxm would impart beneficial intransit-cell effects in T1DM [4]. Indeed, we have recently shown that sustained treatment with (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] improves metabolic control and islet morphology

in an experimental model of T1DM [5]. However, further observations from our laboratory reveal that Oxm-mediated actions are not limited to the pancreas and gut, and that Oxm crosses the blood brain barrier [2]. As such, activation of Oxm signaling pathways in the hippocampal brain regions in an animal model of type 2 diabetes was associated with positive effects on cognitive function and overall learning and memory processes [2]. Therefore, we have now examined the consequence of twice daily (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] administration on metabolic status, anxiety, exploratory behavior, cognitive function and the expression of key hippocampal genes involved in learning and memory in insulin-deficient streptozotocin (STZ)-induced T1DM mice.

MATERIALS AND METHODS

Peptides

(D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] was purchased from GL Biochem Ltd. (Shanghai, China) and characterized as described previously [3].

Animals

Adult male NIH mice (14-16 weeks old; Harlan UK Ltd, Blackthorn, UK) were housed individually in an air-

1 conditioned room at $22 \pm 2^\circ\text{C}$ with 12:12 h light/dark cycle.
 2 Mice had free access to drinking water and standard rodent
 3 maintenance diet that contained 10% fat, 30% protein
 4 and 60% carbohydrate (Trouw Nutrition, Cheshire, UK).
 5 Diabetes was induced by intraperitoneal (i.p.) injection
 6 of 12 h fasted mice with 150 mg/kg streptozotocin (STZ)
 7 freshly prepared in ice cold 0.1 M sodium citrate buffer,
 8 pH 4.5. All animal procedures were carried out according
 9 to the UK home office regulations (UK Animal Scientific
 10 Procedures Act 1986).

11 **In vivo studies**

12 Following STZ administration, mice (n=8) received twice
 13 daily injections (08:00 and 17:00 h) of saline vehicle (0.9%
 14 (w/v) NaCl) or (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] (25 nmol/kg,
 15 b.w.) for 28 days. All STZ injected mice received insulin
 16 (15 U/kg b.w. once daily, bovine insulin, Sigma-Aldrich,
 17 Poole, UK) for the first 5 days of the study. Insulin therapy
 18 was only maintained thereafter in diabetic control mice.
 19 Normal mice maintained on standard diet, without STZ
 20 intervention, and treated twice daily with saline were used
 21 for comparative purposes. Body weight, non-fasting plasma
 22 glucose and insulin concentrations were recorded on day
 23 28. In addition, i.p. glucose tolerance (18 mmol/kg body
 24 wt) and insulin sensitivity (20 U/kg body wt) tests were
 25 performed at the end of the study period.

26 **Open field assessment and object recognition task**

27 For open field assessment, at the end of the study mice
 28 were placed in an exploratory arena (58 cm diameter,
 29 38 cm high) for 5 minute and a computerized tracking
 30 system (Biosignals, New York) analyzed measures of speed,
 31 distance travelled, rearing actions (indicator of exploratory
 32 activity) and grooming events (indicator of anxiety levels)
 33 [6]. For object recognition, animals were placed in the same
 34 arena and two identical random objects (2 marbles, 2.5 cm
 35 diameter; or 2 dice, 1.2 cm side length) were positioned in
 36 the center of the arena (dimensions outlined above). Four
 37 hours after initial exposure (the acquisition phase), one of
 38 the two objects was replaced by a novel object (a marble or
 39 dice) and the time spent exploring both objects during a 5
 40 minute trial phase determined. Recognition index (RI) was
 41 calculated as described previously [6].

42 **Hippocampal gene expression**

43 Whole hippocampus tissue was excised at the end of
 44 the treatment period, snap frozen and processed for
 45 gene expression by qPCR following total RNA extraction
 46 (Tripure Isolation Reagent; Roche Diagnostics, West
 47 Sussex, UK). cDNA was synthesized using Transcriptor
 48 First Strand cDNA Synthesis Kit (Roche Diagnostics).
 49 Gene expression analysis was carried out using a Roche
 50 Real Time ready qPCR assay and Light Cycler 480 Probes
 51 Master and a hot start reaction mix (Roche Diagnostics,

West Sussex, UK), according to the Manufacturer's
 instructions. The following target genes were designed
 and supplied by Roche (Roche Probe master): insulin
 receptor substrate-1 (IRS-1), synaptophysin (SYP);
 mammalian target of rapamycin (mTOR) and mammalian
 achaete-scute homologue 1 (MASH1). Gene expression
 was normalized to hypoxanthine guanine phosphoribosyl
 transferase (HPRT) expression and relative quantification
 assessed using the $2^{-\Delta\Delta\text{CT}}$ method to calculate differences in
 gene expression between samples, as described previously
 [2].

22 **Statistical analysis**

Results are presented as mean \pm SEM. Groups of data
 were compared using ANOVA and unpaired Student's
 t-test in GraphPad PRISM (version 3.0). Differences were
 considered significant if $P < 0.05$.

23 **RESULTS**

24 **Effects of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] on metabolic control in STZ-induced diabetic mice**

25 Twice daily treatment with (D-Ser²)Oxm[Lys³⁸-γ-glu-
 26 PAL] resulted in the complete normalization of body
 27 weight in STZ-induced diabetic mice by day 28 (Table 1).
 28 Non-fasting blood glucose and plasma insulin levels were
 29 still increased ($P < 0.001$) and decreased ($P < 0.001$),
 30 respectively, compared to normal control mice, but they
 31 were significantly improved ($P < 0.01$ and $P < 0.001$,
 32 respectively) compared to STZ diabetic controls (Table
 33 1), despite continued insulin therapy in STZ control mice.
 34 AUC glucose tolerance values were significantly ($P <$
 35 0.001) improved compared to STZ controls, but elevated
 36 ($P < 0.001$) when compared to normal control mice (Table
 37 1). In addition, the hypoglycemic action of insulin was
 38 significantly ($P < 0.05$) augmented in (D-Ser²)Oxm[Lys³⁸-
 39 γ-glu-PAL] treated mice compared to STZ diabetic
 40 controls (Table 1).

41 **Effects of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] on anxiety levels, exploratory behavior and hippocampal gene expression**

42 Open field assessment revealed no effect of 28 days twice
 43 daily treatment with (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL]
 44 on the number of grooming (anxiety level) and rearing
 45 (exploration) episodes, as well as distance travelled and
 46 average speed, when compared to STZ and lean control
 47 mice (data not shown). However, STZ diabetic control mice
 48 had significantly ($P < 0.05$) impaired recognition memory
 49 by the end of the study, which was completely restored by
 50 (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] treatment (Figure 1A, B).
 51 Indeed, (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] mice displayed a
 52 similar preference to explore the novel object as normal
 53 control mice (Figure 1B).

Table 1. Effects of (d-Ser²)Oxm[Lys³⁸-γ-glu-PAL] on metabolic parameters in STZ-induced diabetic mice

Parameter	STZ diabetic control	(d-Ser ²)Oxm[Lys ³⁸ -γ-glu-PAL]	Lean control
Body weight (g)	16.0 ± 0.2***	19.5 ± 0.3 ^{ΔΔΔ}	20.5 ± 0.3
Non-fasting glucose (mmol/l)	34.5 ± 1.1***	25.7 ± 1.1***,ΔΔ	3.6 ± 0.2
Non-fasting insulin (ng/ml)	0.1 ± 0.1***	0.6 ± 0.1***,ΔΔΔ	1.1 ± 0.1
Glucose tolerance: 0-60 min glucose AUC (mmol/l.min)	705.7 ± 47.0***	526.7 ± 19.0***,ΔΔΔ	331.1 ± 18.4
Insulin sensitivity: glucose 0-60 min AAC (mmol/l.min)	412.5 ± 67.2	808.2 ± 95.9 ^Δ	530.7 ± 179.0

Parameters were measured after 28 days treatment with saline vehicle or (d-Ser²)Oxm[Lys³⁸-γ-glu-PAL] (25 nmol/kg). For glucose tolerance, glucose (18 mmol/kg body wt) was administered in non-fasted mice and 0-60 min plasma glucose AUC values calculated. For insulin sensitivity, insulin (20 U/kg body wt) was administered in non-fasted mice and 0-60 min AAC values calculated. Values are mean ± SEM for six mice. ****P* < 0.001 compared to normal lean controls. ^Δ*P* < 0.05, ^{ΔΔ}*P* < 0.01, ^{ΔΔΔ}*P* < 0.001 compared to STZ diabetic controls maintained on insulin (15 U/kg b.w. once daily) throughout.




Figure 1. Effects of twice daily (d-Ser²)Oxm[Lys³⁸-γ-glu-PAL] administration on (A, B) recognition index (RI) and (C-F) hippocampal gene expression in STZ-induced diabetic mice. (A, B) Recognition index (RI) was assessed during the acquisition (A) and test (B) tasks in mice. RI was defined as the amount of time exploring the familiar (tA) or novel object (tB) over the total time spent exploring both objects × 100: (tA or tB)/(tA+tB) × 100. (C-F) mRNA expression of (C) MASH1, (D) SYP, (E) mTOR and (F) IRS-1 was examined in the hippocampus and expression normalized to levels of the internal control gene HPRT. All values are mean ± SEM for 5-7 mice. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 compared to normal controls. ^Δ*P* < 0.05, ^{ΔΔΔ}*P* < 0.001 compared to STZ diabetic controls.

Effects of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] on hippocampal gene expression

Induction of diabetes by STZ injection significantly (*P* < 0.01 to *P* < 0.001) reduced hippocampal gene expression of MASH1, SYP and mTOR (Figure 1C-E). (d-Ser²)Oxm[Lys³⁸-γ-glu-PAL] treatment significantly (*P* < 0.05) increased MASH1 expression compared to STZ diabetic

control mice, although this was still lower (*P* < 0.05) than normal controls (Figure 1C). However, SYP and mTOR hippocampal gene expression was enhanced compared to both normal (*P* < 0.05 and *P* < 0.001; respectively) and diabetic (*P* < 0.001 in both cases) control mice (Figure 1D,E). STZ diabetic mice had unaltered IRS-1 hippocampal gene expression, but treatment with (d-Ser²)

Oxm[Lys³⁸-γ-glu-PAL] increased expression compared to normal ($P < 0.01$) and diabetic ($P < 0.05$) control mice (Figure 1F).

DISCUSSION

Consistent with previous observations, up-regulation of Oxm signaling pathways resulted in marked beneficial effects in STZ-induced T1DM mice [4,5]. Thus, twice daily administration of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] markedly improved glucose homeostasis and insulin sensitivity. Notably, normalization of body weight was also observed in the current study, together with substantially reduced circulating glucose and increased insulin concentrations. We have already shown that these beneficial Oxm-mediated effects are associated with improvements of islet morphology [5]. However, whilst encouraging effects of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] on cognition have recently been evidenced in type 2 diabetes [2], information in this regard is lacking in insulin-deficient T1DM. In view of the increasing awareness of cognitive defects in diabetes [7], we therefore examined the impact of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] treatment on anxiety, exploratory behavior, recognition memory and the expression of key hippocampal genes involved in cognition in STZ-induced T1DM mice. In addition, recent evidence suggests a neuroprotective effect of Oxm in a mouse model of Parkinson's disease [8].

In harmony with findings in high fat fed mice [2], treatment with (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] resulted in a marked increase in hippocampal SYP gene expression in STZ-induced T1DM mice. This could point towards improved neuronal communication (synaptogenesis) in these mice [9], as expression was significantly elevated compared to both STZ-diabetic and lean control mice. In accordance with this, expression of MASH1, a molecule important for neuronal growth [10], was also enhanced in the hippocampus of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] treated STZ mice. As such, augmented MASH1 signaling indicates proliferation and differentiation of hippocampal progenitor neuronal cells [11]. Interestingly, sustained activation of GLP-1 receptors has also been shown to elevate hippocampal mRNA expression of MASH1 in mice [12]. Taken together, these observations suggest improvements in the processes underlying hippocampal-mediated cognitive performance. Thus, (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] treated mice exhibited significantly increased learning and recognition memory, as evidenced by the novel object recognition behavioral task. Moreover, despite daily insulin therapy, STZ diabetic mice exhibited decreased recognition memory, highlighting the clear advantages of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] therapy in T1DM [5]. Importantly, improved memory was not associated with changes in anxiety or exploratory behavior, which could have otherwise impacted upon these findings.

There is a recognized connection between the development of cognitive decline and insulin resistance [13]. Treatment with (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] resulted in increased

hippocampal mRNA expression of IRS-1, an important signaling protein responsible for initiating insulin and insulin-like growth factor signaling pathways [14]. As such, defective IRS-1 dependent insulin signaling in the hippocampus has been associated with severe cognitive deterioration [15]. Interestingly, hippocampal expression of mTOR, a protein kinase involved in the insulin signaling pathway [16], was prominently enhanced by (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] treatment. These observations suggest that the improvement of peripheral insulin sensitivity noted with (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] also extends to its central actions. However, additional assessments of protein expression would also be important to more closely mimic a functional physiological effect for the genes described in this study.

In conclusion, the present study indicates that the therapeutic efficacy of (D-Ser²)Oxm[Lys³⁸-γ-glu-PAL] in T1DM extends to enhancement of hippocampal signaling pathways involved in cognition and memory function [2]. The extent to which improvements in metabolic control contribute to these effects requires further clarification [17,18], but this study clearly highlights the potential of stable analogues of Oxm as novel therapeutic agents for alleviation of cognitive defects in T1DM.

DECLARATION OF INTEREST

The authors report no conflict of interests.

1 REFERENCES

- 2 1. Pocai A. Action and therapeutic potential of oxyntomodulin. *Mol Metab* 2013; 3:241-51. 2
- 3 2. Pathak NM, Pathak V, Lynch AM, Irwin N, Gault VA, Flatt PR. Stable 3 oxyntomodulin analogues exert positive effects on hippocampal 4 neurogenesis and gene expression as well as improving glucose 5 homeostasis in high fat fed mice. *Mol Cell Endocrinol* 2015; 412:95-103 6
- 7 3. Lynch AM, Pathak N, Flatt YE, Gault VA, O'Harte FP, Irwin N, Flatt 8 PR. Comparison of stability, cellular, glucose-lowering and appetite 9 suppressing effects of oxyntomodulin analogues modified at the 10 N-terminus. *Eur J Pharmacol* 2014; 743:69-78. 11
- 12 4. Maida A, Lovshin JA, Baggio LL, Drucker DJ. The glucagon-like 13 peptide-1 receptor agonist oxyntomodulin enhances beta-cell function 14 but does not inhibit gastric emptying in mice. *Endocrinology* 2008; 15 149:5670-8. 16
- 17 5. Irwin N, Pathak V, Pathak N, Gault VA, Flatt PR. Sustained treatment 18 with a stable long-acting oxyntomodulin analogue improves metabolic 19 control and islet morphology in an experimental model of type 1 20 diabetes. *Diabetes Obes Metab* 2015; 17:887-95. 21
- 22 6. Lennox R, Porter DW, Flatt PR, Holscher C, Irwin N, Gault VA. 23 Comparison of the independent and combined effects of sub-chronic 24 therapy with metformin and a stable GLP-1 receptor agonist on 25 cognitive function, hippocampal synaptic plasticity and metabolic 26 control in high-fat fed mice. *Neuropharmacology* 2014; 86:22-30. 27
- 28 7. Biessels GJ, Reijmer YD. Brain changes underlying cognitive 29 dysfunction in diabetes: what can we learn from MRI? *Diabetes* 2014; 30 63:2244-52. 31
- 32 8. Liu W, Li Y, Jalewa J, Saunders-Wood T, Li L, Hölscher C. 33 Neuroprotective effects of an oxyntomodulin analogue in the MPTP 34 mouse model of Parkinson's disease. *Eur J Pharmacol* 2015; 765:284- 35 90. 36
- 37 9. Liebau S, Vaida B, Storch A, Boeckers TM. Maturation of synaptic 38 contacts in differentiating neural stem cells. *Stem Cells* 2007; 25:1720-9 39
- 40 10. Williams RR, Venkatesh I, Pearse DD, Udvadia AJ, Bunge MB. MASH1/ 41 *Ascl1a* leads to GAP43 expression and axon regeneration in the adult 42 CNS. *PLoS One* 2015; 10:e0118918. 43
- 44 11. Sommer L, Shah N, Rao M, Anderson DJ. The cellular function of 45 MASH1 in autonomic neurogenesis. *Neuron* 1995; 15:1245-58. 46
- 47 12. Porter WD, Flatt PR, Hölscher C, Gault VA. Liraglutide improves 48 hippocampal synaptic plasticity associated with increased expression 49 of Mash1 in ob/ob mice. *Int J Obes (Lond)* 2013; 37:678-84. 50
- 51 13. Biessels GJ, Reagan LP. Hippocampal insulin resistance and cognitive 52 dysfunction. *Nat Rev Neurosci* 2015; 16:660-71. 53
- 54 14. Zemva J, Schubert M. Central insulin and insulin-like growth factor-1 55 signaling: implications for diabetes associated dementia. *Curr Diabetes 56 Rev* 2011; 7:356-66
15. Kim B, Feldman EL. Insulin resistance as a key link for the increased cognitive impairment in the metabolic syndrome. *Exp Mol Med* 2015; 47:e149.
16. Ménard C, Gaudreau P, Quirion R. Signaling pathways relevant to cognition-enhancing drug targets. *Handb Exp Pharmacol* 2015; 228:59-98.
17. Irwin N, Flatt PR. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. *World J Diabetes* 2015; 6:1285-95.
18. Irwin N, Flatt PR. Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. *Curr Opin Pharmacol* 2013; 13:989-95.

© TEMKODER. This is an open access article licensed under the terms of the **Creative Commons Attribution Non-Commercial License** (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, noncommercial use, distribution and reproduction in any medium, provided that the work is properly cited.

Conflict of Interest: None declared